RE:RE:RE:RE:RE:Enterprise Value to Sales ValuationNote of caution. The success rate may be 5% but this number would be for biotech's at the very start of the clinical process. If you take something like Antibe, which is closing in on the end of Phase II then the average success rate for biotech's from end Phase II to FDA approval is around 75%. I think you can improve you're odds in the crapp shoot with the right mix of biotechs. Those thousands of drug trials are both chances for failure and opportunities for derisking, isnt that fun.
Benedict16th wrote: Pay a litle more attention. It has been about four Years since GUD started to invest in the following venture funds. So we are not too far from pay off, such as the value of the funds itself and drug licencing. These funds togheter have thousands of drug trial developments on the go. Even with 5% success rate you may be looking at hundreds of new drugs.
See funds
Teralys C$30M VCAP Fund of Funds Canada Domain US$25M Early stage North America Forbion €19.5M All clinical stages Europe Sectoral US$13M Late stage to small cap Global Sanderling US$10M Early stage North America HarbourVest C$10M VCAP Fund of Funds Canada TVM US$1.6M All clinical stages Global Bloom Burton 2 C$1.5M Commercial stage Canada Genesys C$1M Early stage North America Total 1 ~C$126.7M